Sanofi SA SASY.PA:
* FDA GRANTS PRIORITY REVIEW TO SARCLISA
* TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA NOT ELIGIBLE FOR TRANSPLANT
*FDA PRIORITY REVIEW IS DRIVEN BY POSITIVE RESULTS OF PHASE III IMROZ STUDY
*THE FDA IS EXPECTED TO MAKE ITS DECISION ON SEPTEMBER 27, 2024
*A REGULATORY SUBMISSION IS ALSO UNDER STUDY IN THE EUROPEAN UNION
Original text on WorkSapce: For more details, click SASY.PA
(Gdansk editorial office)